The incentive salience of alcohol : Translating the effects of genetic variant in CNR1

Archives of General Psychiatry

Volumn 65, Issue 7, 2008, Pages 841-850

  Hutchison, Kent E ^a,c,d   Haughey, Heather ^a   Niculescu, Michelle ^a   Schacht, Joe ^a   Kaiser, Alan ^a   Stitzel, Jerry ^b   Horton, William J ^b   Filbey, Francesca ^a,c,d  

^a Department of Psychology ^*

^b Institute of Behavioral Genetics

^c UNIVERSITY OF COLORADO   (United States)

^d The MIND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABINOID 1 RECEPTOR; OLANZAPINE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ALLELE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROENCEPHALOGRAM; FEMALE; GENETIC VARIABILITY; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; NERVE CELL; NEUROIMAGING; PATHOGENESIS; PREFRONTAL CORTEX; RECEPTOR BINDING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALCOHOL DRINKING; BRAIN; GENE EXPRESSION; GENOMICS; GENOTYPE; HUMANS; MALE; RECEPTOR, CANNABINOID, CB1; VARIATION (GENETICS);

EID: 46849096955     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.65.7.841     Document Type: Article

References (53)

1. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2-14.
2. Colombo G, Serra S, Vacca G, Carai MA, Gessa GL. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav. 2005;81(2):369-380.
3. Hungund BL, Basavarajappa BS. Role of endocannabinoid and cannabinoid CB1 receptors in alcohol-related behaviors. Ann N Y Acad Sci. 2004;1025:515-527.
4. Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev. 2006;30(5):680-695.
5. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29(4):225-232.
6. De Vries TJ, Schoffelmeer AN. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci. 2005;26(8):420-426.
7. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403-1413.
8. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace L, Ciccioppo R. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychophar-macology (Berl). 2006;183(4):394-403.
9. Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A, Reali R, Gessa GL. Reduction of voluntary ethanol intake in ethanol-preferring sP rates by the can-nabinoid antagoinst SR-141716. Alcohol Alcohol. 1998;33(2):126-130.
10. Gallate JE, McGregor IS. The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716. Psychopharmacology (Berl). 1999;142(3):302-308.
11. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 2005;40(1):46-53.
12. Lallemand F, Soubrie PH, De Witte PH. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin Exp Res. 2001;25(9):1317-1323.
13. Arnone M, Maruani J, Chaperon F, Thiebot MH, PonceletM, Soubrié P, Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1997;132(1):104-106.
14. DeVriesTJ,Shaham Y, Homberg JR,Crombag H,Schuurman K, Dieben J, Vander-schuren LJ, SchoffelmeerAN. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med. 2001;7(10):1151-1154.
15. De Vries TJ, Homberg JR, Binnekade R, Raaso H, SchoffelmeerAN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl). 2003;168(1-2):164-169.
16. De Vries TJ, de Vries W, Janssen MC, SchoffelmeerAN. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav Brain Res. 2005;161(1):164-168.
17. Colombo G, Serra S, Brunetti G, Gomez R, Melis S, Vacca G, Carai MM, Gessa L. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology (Berl). 2002;159(2):181-187.
18. Poncelet M, Maruani J, Calassi R, Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett. 2003;343(3):216-218
19. Hungund BL, Szakall I, Adam A, Basavarajappa BS, VadaszC. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens J Neurochem. 2003;84(4):698-704.
20. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res. 2005;164(2):206-213
21. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology. 2005;30(2):339-349.
22. Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci. 2003;23(6):2453-2458.
23. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M Bermúdez-Silva FJ, Navarro M, Ciccocioppo R, de Fonseca FR; European TARGALC Consortium. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci. 2005;21(8):2243-2251
24. Schmidt LG,Samochowiec J, Finckh U, Fiszer-PiosikE, Horodnicki J, Wendel B Rommelspacher H, Hoehe MR. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 2002;65(3):221-224.
25. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinam T, Uhl GR. Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse Mol Psychiatry. 2004;9(10):916-931
26. Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry. 2007;62(6):616-626.
27. Preuss UW, Koller G, Zill P, Bondy B, Soyka M. Alcoholism-related phenotypes and genetic variants of the CB1 receptor. Eur Arch Psychiatry Clin Neurosci. 2003;253(6):275-280.
28. Herman AI, Kranzler HR, Cubells JF, Gelernter J, Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141(5):499-503.
29. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci. 2006;23(7):1944-1948
30. Steffens M, Engler C, Zentner J, Feuerstein TJ. Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Br J Pharmacol. 2004;141(7):1193-1203
31. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther. 1998;285(1):285-292
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-275
33. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28(10):1882-1888.
34. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31(6):1310-1317.
35. Filbey FM, Claus E, Audette AR, Niculescu M, Banich MT, Tanabe J, Du YP, Hutchison KE. Exposure to the taste of alcohol elicits robust activation of the meso-corticolimbic neurocircuitry [published online ahead of print July 25, 2007]. Neuropsychopharmacology. 2008;33(6):1391-1401. doi:10.1038/sj.npp.1301513.
36. Barbor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. 2nd ed. Geneva, Switzerland: World Health Organization; 2006.
37. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19(3):600-606.
38. Schneider W, Eschman A, Zuccolotto A. E-Prime User's Guide. Pittsburgh, PA: Psychology Software Tools Inc; 2002.
39. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143-155.
40. Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal autocorrelation in uni-variate linear modeling of FMRI data. Neuroimage. 2001;14(6):1370-1386.
41. Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis in FMRI. Neuroimage. 2003;20(2):1052-1063.
42. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modeling for fMRI group analysis using Bayesian inference. Neuroimage. 2004;21(4):1732-1747.
43. Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab. 1992;12(6):900-918.
44. McNair DM, Lorr M, Droppleman LF. Profile of Mood States. San Diego, CA: Educational & Industrial Testing Service; 1971.
45. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: treatment main effects and matching effects on drinking during treatment. J Stud Alcohol. 1998;59(6):631-639.
46. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25(11):1634-1647.
47. Killeen TK, Brady KT, Gold PB, Tyson C, Simpson KN. Comparison of self-report versus agency records of service utilization in a community sample of individuals with alcohol use disorders. Drug Alcohol Depend. 2004;73(2):141-147.
48. Sobell LC, Sobell MB. An approach to increasing confidence in treatment outcome conclusions with alcohol and drug abusers. In: Sobell LC, Sobell MB, Ward E, eds. Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. New York, NY: Pergamon Press; 1980:177-183.
49. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol. 2002;21(2):139-146.
50. Ray LA, Hutchison KE. A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789-1795.
51. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069-1077.
52. Hutchison KE, Stallings M, McGeary J, Bryan A. Population stratification in the candidate gene study: fatal threat or red herring? Psychol Bull. 2004;130(1):66-79.
53. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-678.